EyePoint Pharmaceuticals announced the appointment of Stuart Duty to its Board of Directors and the promotion of George Elston to Executive Vice President, EVP. Stuart Duty is an experienced financial executive with over 30 years of experience in finance and investment banking. Duty was most recently a Senior Managing Director at Guggenheim Securities, LLC. Elston joined EyePoint in 2019 as Chief Financial Officer & Head of Corporate Development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EYPT:
- EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint reports inducement grants under Nasdaq listing rule
- Biotech Alert: Searches spiking for these stocks today
- EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023
